Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.

Jared J. Grantham, Arlene B. Chapman, Vicente Torres

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

Autosomal dominant polycystic kidney disease (PKD) is a hereditary condition characterized by the progressive enlargement of innumerable renal cysts that contribute to life-altering morbidity early in the course of the disease. Evidence indicates that the rate of increase in kidney volume can be reliably measured by magnetic resonance or computed tomography imaging, thus providing objective means to judge the effectiveness of therapies that are targeted to the aberrant growth of renal tubules. It is now possible, therefore, to monitor the effectiveness of potential therapies on the signature abnormality in autosomal dominant PKD before irreversible damage has been done by the cysts. Evidence accumulated from human cross-sectional and longitudinal studies and longitudinal studies of PKD models in animals provide strong support for the view that reducing the rate of kidney volume enlargement will ameliorate the late-stage development of renal insufficiency.

Original languageEnglish (US)
Pages (from-to)148-157
Number of pages10
JournalClinical journal of the American Society of Nephrology : CJASN
Volume1
Issue number1
DOIs
StatePublished - Jan 2006
Externally publishedYes

Fingerprint

Autosomal Dominant Polycystic Kidney
Kidney
Longitudinal Studies
Cysts
Polycystic Kidney Diseases
Renal Insufficiency
Magnetic Resonance Spectroscopy
Animal Models
Cross-Sectional Studies
Tomography
Morbidity
Therapeutics
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Volume progression in autosomal dominant polycystic kidney disease : the major factor determining clinical outcomes. / Grantham, Jared J.; Chapman, Arlene B.; Torres, Vicente.

In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 1, No. 1, 01.2006, p. 148-157.

Research output: Contribution to journalArticle

@article{5ce5d5a953904edc83768da7e0c7b91a,
title = "Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.",
abstract = "Autosomal dominant polycystic kidney disease (PKD) is a hereditary condition characterized by the progressive enlargement of innumerable renal cysts that contribute to life-altering morbidity early in the course of the disease. Evidence indicates that the rate of increase in kidney volume can be reliably measured by magnetic resonance or computed tomography imaging, thus providing objective means to judge the effectiveness of therapies that are targeted to the aberrant growth of renal tubules. It is now possible, therefore, to monitor the effectiveness of potential therapies on the signature abnormality in autosomal dominant PKD before irreversible damage has been done by the cysts. Evidence accumulated from human cross-sectional and longitudinal studies and longitudinal studies of PKD models in animals provide strong support for the view that reducing the rate of kidney volume enlargement will ameliorate the late-stage development of renal insufficiency.",
author = "Grantham, {Jared J.} and Chapman, {Arlene B.} and Vicente Torres",
year = "2006",
month = "1",
doi = "10.2215/CJN.00330705",
language = "English (US)",
volume = "1",
pages = "148--157",
journal = "Clinical Journal of the American Society of Nephrology",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "1",

}

TY - JOUR

T1 - Volume progression in autosomal dominant polycystic kidney disease

T2 - the major factor determining clinical outcomes.

AU - Grantham, Jared J.

AU - Chapman, Arlene B.

AU - Torres, Vicente

PY - 2006/1

Y1 - 2006/1

N2 - Autosomal dominant polycystic kidney disease (PKD) is a hereditary condition characterized by the progressive enlargement of innumerable renal cysts that contribute to life-altering morbidity early in the course of the disease. Evidence indicates that the rate of increase in kidney volume can be reliably measured by magnetic resonance or computed tomography imaging, thus providing objective means to judge the effectiveness of therapies that are targeted to the aberrant growth of renal tubules. It is now possible, therefore, to monitor the effectiveness of potential therapies on the signature abnormality in autosomal dominant PKD before irreversible damage has been done by the cysts. Evidence accumulated from human cross-sectional and longitudinal studies and longitudinal studies of PKD models in animals provide strong support for the view that reducing the rate of kidney volume enlargement will ameliorate the late-stage development of renal insufficiency.

AB - Autosomal dominant polycystic kidney disease (PKD) is a hereditary condition characterized by the progressive enlargement of innumerable renal cysts that contribute to life-altering morbidity early in the course of the disease. Evidence indicates that the rate of increase in kidney volume can be reliably measured by magnetic resonance or computed tomography imaging, thus providing objective means to judge the effectiveness of therapies that are targeted to the aberrant growth of renal tubules. It is now possible, therefore, to monitor the effectiveness of potential therapies on the signature abnormality in autosomal dominant PKD before irreversible damage has been done by the cysts. Evidence accumulated from human cross-sectional and longitudinal studies and longitudinal studies of PKD models in animals provide strong support for the view that reducing the rate of kidney volume enlargement will ameliorate the late-stage development of renal insufficiency.

UR - http://www.scopus.com/inward/record.url?scp=33646710257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646710257&partnerID=8YFLogxK

U2 - 10.2215/CJN.00330705

DO - 10.2215/CJN.00330705

M3 - Article

C2 - 17699202

AN - SCOPUS:33646710257

VL - 1

SP - 148

EP - 157

JO - Clinical Journal of the American Society of Nephrology

JF - Clinical Journal of the American Society of Nephrology

SN - 1555-9041

IS - 1

ER -